180 Wealth Advisors LLC Acquires Shares of 227 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

180 Wealth Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 227 shares of the biopharmaceutical company’s stock, valued at approximately $218,000.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after purchasing an additional 39,780 shares during the period. Capital World Investors lifted its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Putnam Investments LLC boosted its position in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $932,571,000. Finally, Morgan Stanley increased its position in shares of Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after acquiring an additional 25,792 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Finally, Argus increased their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,027.55.

Insiders Place Their Bets

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.0 %

Regeneron Pharmaceuticals stock opened at $1,051.03 on Friday. The firm has a 50-day moving average price of $984.27 and a two-hundred day moving average price of $950.40. Regeneron Pharmaceuticals, Inc. has a 52-week low of $688.52 and a 52-week high of $1,081.17. The firm has a market capitalization of $115.81 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 2.17 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.